abrdn Life Sciences Investors Operating Income

abrdn Life Sciences Investors (HQL) currently reports a operating income of $150M as of March 2026. That compares with $73M in the prior-year period — up 106.1% year over year. Use the charts on this page to explore abrdn Life Sciences Investors's operating income history and peer comparisons.

abrdn Life Sciences Investors's operating income increased from $73M to $150M — a 106.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

abrdn Life Sciences Investors reported $150M in operating income as of March 2026. That compares with $73M in the prior-year period — up 106.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for abrdn Life Sciences Investors, and consider following HQL for alerts when major investors trade the stock.